Basically, I agree. Listen to any recent CC. This company has up until now lived and died based on China bus revenues, A pretty risky position. Everyone is fascinated (including myself) by the cool tecnology and it's potential. But it has just not materilized yet into any growth. Scroll back on this message board two or three years and you'll find many of the same wishful observations as in the last two weeks.. That said, I recently bought into MXWL again, because I think there is a place for this technology in this ever greening world.
You mentioned meetings with the FDA by months end in an earlier post. Can you elaborate that?
Yes. A very good thread. Yet these explosive growth ideas having floating out there and on this board for quite some time. The actual company performance and stock price however, paint a different tale. I'd love to wake up some day soon and see an actual mass production auto deal announced. But really, for now, it's all hype.
Kofax has a much broader product portfolio than MITK. But with this stock languishing, any good news is welcome.
Belorus signed a contract with China for $315/ton. A five dollar increase, effectively setting the price for the market.
Not the disaster the stock price seems to have anticipated.
Until one of the "tier one" customers has a real product that someone might buy, it never will go anywhere.
But, it might happen.
That said, and it's been noted on this board, they do have a lot of cash. A more meaningful payout would seem reasonable and sound.
Impressive numbers. Even with the recent rise in the price of the stock, a much higher price seems quite reasonable, especially if you plug in these numbers.
A great deal of panceatic cancers are diagnosed without resection of the primary tumor or any surgical procedure.
The cancers are often too late stage to be resectable. The diagnosis may sometimes be confirmed by fine needle aspiration. Sometimes this is not off the primary tumor, but off a metastatic site, such as the liver. Is it possible to quantify hyaluron content on this type of specimen? Will a metastasis have the same content as the primary tumor?
How is hyaluron content determined in the trial?
My point is that it may be academic to stratify tumors on hyaluron content (beyond scientific interest), as most may ultimately receive PEG for lack of knowing beforehand. Lung cancer usually involves a real tissue diagnosis, so that's a different situation.